Press release archive 2005

Wednesday, 28 December 2005
AstraZeneca Signs Collaboration Agreement with Targacept for New Neuronal Nicotinic Receptor Compounds Phase II compound for improving cognitive deficits in Alzheimer’s Disease and Schizophrenia included in agreement. AstraZeneca today announced that it has signed an exclusive global licensing and research collaboration agreement with Targacept Inc. for the development and commercialization of Targacept's phase II compound, TC-1734 to treat Alzheimer's disease, cognitive deficits in schizophrenia and other cognitive disorders. The four-year research collaboration also allows for the development of other
Friday, 23 December 2005
Acquisition Of KuDOS Pharmaceuticals Will Enhance AstraZeneca’s Ability To Generate Novel Cancer Treatments AstraZeneca today announced an agreement to acquire KuDOS Pharmaceuticals Limited, a privately-owned UK biotechnology company, focused on the discovery and development of oncology therapies based on the inhibition of DNA repair. The total share capital of the company will be purchased for $210m cash, subject to debt and working capital adjustment. The transaction is expected to close early in 2006.
Thursday, 22 December 2005
AstraZeneca and AtheroGenics Announce Late Stage Licensing and Commercialisation Agreement for Novel Atherosclerosis Drug AGI-1067 AstraZeneca today announced that it has entered into a licensing deal with AtheroGenics, Inc. (Nasdaq: AGIX) for the global development and commercialisation of their anti-inflammatory cardiovascular product candidate, AGI-1067. AGI-1067 is an investigational oral drug for the treatment of atherosclerosis, the underlying disease process that leads to heart attacks and strokes and is currently in Phase III development in the ARISE (Aggressive Reduction of Inflammation Stops Events) trial.
Wednesday, 14 December 2005
EU Committee for Orphan Medicinal Products Recommends Orphan Drug Designation for ZD6474 (ZACTIMA™) for the Investigation of a Rare form of Thyroid Cancer AstraZeneca announced today that it has received positive opinion from the Committee for Orphan Medicinal Products (COMP) recommending orphan drug designation for ZD6474 (ZACTIMA™) for the treatment of patients with medullary thyroid cancer in the European Union (EU). Final adoption of the opinion is expected from the European Commission in early 2006.
Friday, 9 December 2005
Data Show Survival Benefit For Arimidex™ In Early Breast Cancer Data presented today at the San Antonio Breast Cancer Symposium (SABCS), Texas has found that 'Arimidex' (anastrozole) is the first aromatase inhibitor (AI) to provide an overall survival benefit, compared with tamoxifen, in the treatment of hormone-sensitive early breast cancer.
Thursday, 8 December 2005
AstraZeneca and Protherics Announce Late Stage Licensing Agreement On CytoFab™ AstraZeneca today announced a global development and commercialisation agreement for Protherics anti-sepsis product CytoFab™. CytoFab™ is currently being prepared for a single phase III registration study in severe sepsis in line with guidance received at an end of phase II meeting with the US Food and Drug Administration (FDA).
Tuesday, 22 November 2005
AstraZeneca Commences Patent Infringement Litigation Against Ranbaxy Laboratories AstraZeneca announced today that it has filed a lawsuit in the United States District Court for the District of New Jersey against Ranbaxy Laboratories for willful infringement of AstraZeneca’s patents protecting NEXIUM® (esomeprazole magnesium).
Thursday, 17 November 2005
SYMBICORT® MAINTENANCE AND RELIEVER THERAPY™ IS HIGHLY EFFECTIVE COMPARED WITH ANY DOSE OF SERETIDE™ 17th November 2005. Lund, Sweden. New clinical trial data, published today in the European Respiratory Journal (ERJ)[1], reveals that AstraZeneca’s novel treatment concept - SYMBICORT® Maintenance And Reliever Therapy™ - is highly effective compared with Seretide™ (fluticasone/ salmeterol). The study also provides further evidence that a treatment regimen using just one inhaler for patients day-to-day needs, maintenance and relief, is at least as effective in a real world setting to multiple inhaler
Tuesday, 15 November 2005
NEW AZD6140 PHASE IIb DATA PRESENTED AT AMERICAN HEART ASSOCIATION Dallas, TXNovember 15, 2005 New Phase IIb data from the DISPERSE2 Study 1 presented today at the American Heart Association Meeting, assessed the safety, tolerability and preliminary efficacy of AstraZeneca’s AZD6140 plus aspirin compared to clopidogrel plus aspirin in patients with non-ST elevation acute coronary syndrome (NSTE-ACS).
Wednesday, 9 November 2005
AstraZeneca Commences Patent Infringement Litigation Against Teva AstraZeneca announced today that it has filed a lawsuit in the United States District Court for the District of New Jersey against Teva Pharmaceuticals USA, Inc. and Teva Pharmaceuticals Industries, Ltd. for willful infringement of AstraZeneca’s substance patent protecting Seroquel.